Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

Published Date: 23 Feb 2026

The all-oral, fixed-duration treatment combination provided better PFS and safety than investigator’s choice of chemoimmunotherapy in the phase 3 AMPLIFY study.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

2.

A protein with new anticancer activity has been identified

3.

Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.

4.

Nasal therapeutic HPV vaccine could prevent cervical cancer

5.

The Early Progression of Prostate Cancer Is Not Stopped by Metformin.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot